Trial Profile

A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Giredestrant (Primary) ; Abemaciclib; Fulvestrant; LHRH receptor agonists; Palbociclib; Ribociclib
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Registrational; Therapeutic Use
Acronyms pionERA Breast Cancer
Sponsors Roche

20 Oct 2025 Planned End Date changed from 30 Dec 2028 to 12 Feb 2029.
20 Oct 2025 Planned primary completion date changed from 30 Jul 2026 to 19 Feb 2027.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com